T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MANT
1401
DELISTED
Mantech International Corp
MANT
| $10M | ﹤0.01% |
137,236
-47,854
| -26% | -$3.65M |
|
|
USX
1402
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $9.86M | ﹤0.01% |
1,680,305
+24,600
| +1% | +$185K |
|
|
LBPH
1403
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $9.8M | ﹤0.01% |
2,024,616
-260,674
| -11% | -$1.77M |
|
1404
Oil-Dri
ODC
$1.31B
| $9.77M | ﹤0.01% |
597,000
-146,250
| -20% | -$2.48M |
|
|
STOR
1405
DELISTED
STORE Capital Corporation
STOR
| $9.65M | ﹤0.01% |
280,649
-7,474
| -3% | -$254K |
|
1406
NNN REIT
NNN
$8.83B
| $9.48M | ﹤0.01% |
197,137
-1,740
| -0.9% | -$79.8K |
|
1407
Schrodinger
SDGR
$1.32B
| $9.41M | ﹤0.01% |
270,229
+9,386
| +4% | +$428K |
|
|
SUMO
1408
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $9.27M | ﹤0.01% |
683,457
+131,446
| +24% | +$2.04M |
|
1409
Royal Gold
RGLD
$19.5B
| $9.19M | ﹤0.01% |
87,321
+2,794
| +3% | +$282K |
|
1410
Range Resources
RRC
$9.42B
| $9.1M | ﹤0.01% |
510,118
-488,018
| -49% | -$10.5M |
|
1411
Trinity Capital Inc.
TRIN
$1.72B
| $9.1M | ﹤0.01% |
517,365
+34,592
| +7% | +$574K |
|
|
CMRC
1412
Commerce.com Inc Series 1
CMRC
$181M
| $9.07M | ﹤0.01% |
256,400
+103,667
| +68% | +$4.88M |
|
|
RUBY
1413
DELISTED
Rubius Therapeutics, Inc
RUBY
| $9M | ﹤0.01% |
+930,179
| New | +$12.9M |
|
1414
Genius Sports
GENI
$2.33B
| $8.92M | ﹤0.01% |
1,173,558
-1,071,106
| -48% | -$14.4M |
|
1415
Markel Group
MKL
$22.9B
| $8.9M | ﹤0.01% |
7,209
+57
| +0.8% | +$71.9K |
|
1416
Wolfspeed
WOLF
$1.65B
| $8.83M | ﹤0.01% |
78,977
+2,990
| +4% | +$333K |
|
1417
Consensus Cloud Solutions
CCSI
$716M
| $8.69M | ﹤0.01% |
+150,206
| New | +$9.14M |
|
1418
The Honest Company
HNST
$519M
| $8.69M | ﹤0.01% |
+1,073,577
| New | +$9.44M |
|
|
CELL
1419
DELISTED
PhenomeX Inc. Common Stock
CELL
| $8.6M | ﹤0.01% |
473,160
+55,430
| +13% | +$1.2M |
|
1420
Berkshire Hathaway Class A
BRK.A
$1.08T
| $8.56M | ﹤0.01% |
19
| – | – |
|
|
GTHX
1421
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $8.52M | ﹤0.01% |
834,427
+10,685
| +1% | +$136K |
|
1422
Mercury Systems
MRCY
$6.67B
| $8.51M | ﹤0.01% |
154,473
-239,431
| -61% | -$12.1M |
|
1423
Ciena
CIEN
$60.7B
| $8.42M | ﹤0.01% |
109,341
+21,295
| +24% | +$1.31M |
|
1424
Q32 Bio
QTTB
$451M
| $8.39M | ﹤0.01% |
128,027
+2,213
| +2% | +$215K |
|
1425
Lucid Motors
LCID
$2.45B
| $8.36M | ﹤0.01% |
21,958
+9,068
| +70% | +$3.42M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.